In focus: HDL, atherosclerosis and emerging therapies to reduce cardiovascular disease

August 28, 2010

Venue: ESC Congress – Stockholm / Sweden, 28 Aug 2010, 14.00-15.30

Course Director: Prof. Karl Swedberg

CME Provider: The Sahlgrenska Academy – University of Gothenburg in collaboration with A+ Science

Educational objective
  • To highlight that, despite treatment with effective therapies (e.g. statins) many patients remain at risk of disease
  • To define the role of HDL in reverse cholesterol transport, and show how high levels of HDL are associated with a reduced risk of cardiovascular (CV) disease
  • To evaluate the data from CV imaging studies which have shown that therapeutic interventions to raise HDL-C can have a positive impact on atherogenesis
  • To consider whether the use of cholesteryl ester transport protein (CETP) modulators to raise functional HDL levels is anappropriate potential therapeutic strategy to prevent atherogenesis and reduce CV risk.
Determination of educational needs

The session will consider the potential for agents that raise HDL(-C) to further reduce the risk of cardiovascular (CV) disease. A large number of patients receiving optimal statin therapy remain at risk for CV disease, and the implications of this for CV risk reduction will be considered. The role of low HDL-C as an independent risk factor for CV disease will be reviewed, and its potential for multiple beneficial effects on the CV system will be discussed. Several imaging techniques are available to assess the extent of atherosclerosis, and the evidence they have provided that raising HDL-C can inhibit atherogenesis will be presented.

A number of potential strategies to reduce residual risk are under investigation, including inhibition or modulation of cholesterylester transport protein (CETP) to raise HDL(-C). The rationale for these  approaches will be examined and the future opportunities for CETP inhibitors/modulators to reduce CV risk will be discussed.

The educational needs for this programme were determined by recent published literature plus consultation with the esteemed chairmen and faculty

Target audience: Trained cardiologists, Lipidologists, Research Scientists and other physicians

Return to eventlist